<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="652">
  <stage>Registered</stage>
  <submitdate>24/08/2005</submitdate>
  <approvaldate>24/08/2005</approvaldate>
  <nctid>NCT00135876</nctid>
  <trial_identification>
    <studytitle>Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients</studytitle>
    <scientifictitle>A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>524E-CVD-0056-013</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Venous Thromboembolism</healthcondition>
    <healthcondition>Brain Tumors</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - dalteparin

Treatment: drugs: dalteparin


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>objectively-proven symptomatic VTE (DVT or PE)</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>bleeding (major and all bleeding)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>quality of life</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>cognition assessments</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>death</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Both of the following criteria must be satisfied:

               1. Patients with newly-diagnosed pathologically-confirmed WHO Grade 3 or Grade 4
                  glioma (anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, anaplastic
                  oligodendroglioma, and anaplastic mixed glioma). Tumour histology is based on
                  local pathology review only;

               2. Patients 18 years of age or older at time of randomization</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  If one or more of the following criteria are satisfied, the patient is not eligible
             for the study:

               1. The presence of acute or chronic DVT demonstrated by duplex ultrasonography (DUS)
                  or venography. (Note: a screening DUS is not required for study entry);

               2. Inability to commence study drug within four weeks of original surgery or biopsy;

               3. Serious hemorrhage requiring hospitalization, transfusion, or surgical
                  intervention within four weeks of potential study entry;

               4. Presence of a coagulopathy (e.g. INR &gt;1.5 or platelet count &lt; 100x109/L);

               5. Symptomatic intracranial or intratumoural bleeding. (Note: post-operative imaging
                  of the brain is not required for study entry. Asymptomatic routine
                  post-operative blood products in a post-surgical cavity are not an exclusion;

               6. Known acute (symptomatic or actively bleeding) gastroduodenal ulcer;

               7. Familial bleeding diathesis;

               8. Requiring long term anticoagulants for other reasons (e.g., mechanical heart
                  valves, atrial fibrillation);

               9. Uncontrolled hypertension despite antihypertensive therapy;

              10. Significant renal failure (dependent on dialysis or creatinine of greater than
                  three times upper limit of normal control);

              11. Prior history of documented DVT or PE;

              12. Allergy to anticoagulants (UFH, LMWH) including immune-mediated heparin-induced
                  thrombocytopenia;

              13. Pregnant or of childbearing potential and not using adequate contraception;

              14. Geographically inaccessible for follow-up;

              15. Having an expected life span of less than 6 months;

              16. Body weight &lt; 40 kg.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,WA</recruitmentstate>
    <hospital>The St. George Hospital - Kogarah</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>6847 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Perugia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Ontario Clinical Oncology Group (OCOG)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Pfizer</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH
      (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period,
      for the prevention of VTE.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00135876</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>James Perry, MD</name>
      <address>Toronto Sunnybrook Regional Cancer Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>